CRISPR gene editing can now cure sickle cell disease.

Med & Law (@MedLaw)

In 2023, the FDA approved Casgevy, the first CRISPR-based therapy. It edits a patient's own stem cells to produce functioning hemoglobin. A single treatment can cure a lifelong disease.

0 reactions

0 comments